MCID: CHR074
MIFTS: 46

Choriocarcinoma

Categories: Cancer diseases, Fetal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Choriocarcinoma

MalaCards integrated aliases for Choriocarcinoma:

Name: Choriocarcinoma 12 74 52 36 54 43 15 17 71
Chorioepithelioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3594
KEGG 36 H00028
MeSH 43 D002822
NCIt 49 C2948
SNOMED-CT 67 44769000
ICD10 32 C58
UMLS 71 C0008497

Summaries for Choriocarcinoma

KEGG : 36 Gestational choriocarcinoma is a highly malignant epithelial tumor that can be associated with any type of gestational event, most often a complete hydatidiform mole (CM). CM occur in about one per 1000 pregnancies, and about 5-20% of CM progress to invasive moles or choriocarcinoma. Several molecular studies have been done to establish the expression of tumor-associated proteins in choriocarcinoma. In the p53 pathway, overexpression of the p53 protein and the p53-associated protein, MDM2, have been detected. Synergistic upregulation of c-MYC, c-ERB-2, c-FMS, and BCL-2 oncoproteins have also been suggested to have an important role in the pathogenesis of choriocarcinoma. Moreover, choriocarcinomas have been shown to express increased concentrations of MMP and decreased concentrations of TIMP to help with tumor invasion and metastasis.

MalaCards based summary : Choriocarcinoma, also known as chorioepithelioma, is related to choriocarcinoma of the testis and gestational ovarian choriocarcinoma. An important gene associated with Choriocarcinoma is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Peptide hormone metabolism and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Ribavirin and Palivizumab have been mentioned in the context of this disorder. Affiliated tissues include placenta, lung and testis, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A placenta cancer that has material basis in trophoblastic cells.

Wikipedia : 74 Choriocarcinoma is a malignant, trophoblastic cancer, usually of the placenta. It is characterized by... more...

Related Diseases for Choriocarcinoma

Diseases related to Choriocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
# Related Disease Score Top Affiliating Genes
1 choriocarcinoma of the testis 34.5 CSH2 CSH1
2 gestational ovarian choriocarcinoma 34.5 CSH2 CSH1
3 non-gestational choriocarcinoma 34.2 CSH2 CSH1
4 non-gestational ovarian choriocarcinoma 34.1 CSH2 CSH1
5 choriocarcinoma of ovary 34.1 CSH2 CSH1
6 gestational choriocarcinoma 34.0 HLA-G H19 ENPEP CSH2 CSH1
7 gestational trophoblastic neoplasm 33.2 H19 CSH2 CSH1 CGB5
8 hydatidiform mole, recurrent, 1 33.0 H19 CGB5 CGB3 CGA
9 placental site trophoblastic tumor 32.6 LNPEP CSH2 CSH1 CGB5 CGB3
10 ectopic pregnancy 31.6 CGB7 CGB5 CGB3 CGA
11 mixed germ cell tumor 31.5 CGB3 CGA
12 gynecomastia 31.3 CYP19A1 CGB5 CGA
13 teratoma 31.3 H19 CGB7 CGB5 CGB3 CGA
14 seminoma 31.2 CGB7 CGB5 CGB3 CGA
15 nonseminomatous germ cell tumor 31.2 CGB7 CGB5
16 testicular cancer 31.1 CGB5 CGB3 CGA
17 trophoblastic neoplasm 31.1 LNPEP H19 CSH2 CSH1 CGB5 CGA
18 epithelioid trophoblastic tumor 31.0 CSH2 CSH1 CGB3
19 germinoma 30.8 CGB5 CGB3 CGA
20 chromosomal triplication 30.8 CGB7 CGB3
21 testicular trophoblastic tumor 30.6 CSH2 CSH1
22 triploidy 30.5 CGB7 CGA
23 testicular seminoma 30.5 CGB3 CGA
24 down syndrome 30.1 ETS2 CGB7 CGB5 CGB3 CGA
25 placenta disease 29.9 HLA-G CSH2 CSH1 CGB7 CGB5 CGB3
26 pre-eclampsia 29.7 MALAT1 LNPEP HLA-G H19 ERVW-1 ENPEP
27 cryptorchidism, unilateral or bilateral 29.6 CYP19A1 CGB5 CGA
28 placental choriocarcinoma 12.6
29 fallopian tube gestational choriocarcinoma 12.5
30 childhood choriocarcinoma of the testis 12.4
31 adult central nervous system choriocarcinoma 12.4
32 pediatric cns choriocarcinoma 12.4
33 childhood choriocarcinoma of the ovary 12.4
34 pulmonary artery choriocarcinoma 12.4
35 testicular monophasic choriocarcinoma 12.4
36 gestational uterine corpus choriocarcinoma 12.4
37 uterine corpus choriocarcinoma 12.4
38 pineal region choriocarcinoma 12.4
39 primary non-gestational choriocarcinoma of ovary 12.3
40 choriocarcinoma of the central nervous system 12.1
41 testicular germ cell tumor 11.5
42 teratocarcinoma 11.5
43 recurrent hydatidiform mole 11.5
44 ovarian germ cell cancer 11.1
45 germ cells tumors 10.7
46 invasive mole 10.6
47 sacrococcygeal teratoma 10.6 CGB7 CGA
48 anorchia 10.6 CGB5 CGA
49 mixed ductal-endocrine carcinoma 10.5 CGB7 CGB3
50 tinea favosa 10.5 CGB7 CGB3

Graphical network of the top 20 diseases related to Choriocarcinoma:



Diseases related to Choriocarcinoma

Symptoms & Phenotypes for Choriocarcinoma

GenomeRNAi Phenotypes related to Choriocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.47 HLA-G
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.47 HLA-G
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.47 CGB5 CGB7 HLA-G
4 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.47 HLA-G
5 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.47 HLA-G
6 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.47 HLA-G
7 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.47 CGB5 CGB7
8 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.47 CGB5 CGB7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.47 HLA-G
10 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.47 HLA-G

Drugs & Therapeutics for Choriocarcinoma

Drugs for Choriocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 3 36791-04-5 37542
2
Palivizumab Approved, Investigational Phase 3 188039-54-5
3
Captopril Approved Phase 3 62571-86-2 44093
4
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
5
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
6
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
7
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
8
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
9
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
10
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
11
Nitroglycerin Approved, Investigational Phase 2, Phase 3 55-63-0 4510
12
Mesna Approved, Investigational Phase 3 3375-50-6 598
13
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
14
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
15
Promethazine Approved, Investigational Phase 3 60-87-7 4927
16
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
17
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
18
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
19
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
20
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
21
Ifosfamide Approved Phase 3 3778-73-2 3690
22
Vinblastine Approved Phase 3 865-21-4 13342 241903
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
24
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
25 Antihypertensive Agents Phase 3
26 Angiotensin-Converting Enzyme Inhibitors Phase 3
27 Cytochrome P-450 CYP3A Inhibitors Phase 3
28 Cytochrome P-450 Enzyme Inhibitors Phase 3
29
Hydroxyitraconazole Phase 3
30 Antifungal Agents Phase 3
31 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
32 Steroid Synthesis Inhibitors Phase 3
33 Antiparasitic Agents Phase 3
34 Liposomal amphotericin B Phase 3
35 Antiprotozoal Agents Phase 3
36 Folic Acid Antagonists Phase 2, Phase 3
37 Vitamin B9 Phase 2, Phase 3
38 Vitamin B Complex Phase 2, Phase 3
39 Folate Phase 2, Phase 3
40 Antimetabolites Phase 2, Phase 3
41 Adjuvants, Immunologic Phase 3
42 Dermatologic Agents Phase 2, Phase 3
43 Histamine H2 Antagonists Phase 3
44 Podophyllotoxin Phase 3 518-28-5
45 Antibiotics, Antitubercular Phase 3
46 Trace Elements Phase 3
47 Micronutrients Phase 3
48 Vitamins Phase 3
49 Nutrients Phase 3
50 Hematinics Phase 3

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Unknown status NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
2 Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
3 Comparison Between Rescue Regimen and High Dose Methotrexate in the Managment of Presistent Gestational Trophoplastic Neoplasia :( A Randomized Controlled Trial ) Unknown status NCT03280979 Phase 2, Phase 3 rescue regimen;high dose methotrxate
4 A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
5 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
6 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
7 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
8 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
9 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
10 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
11 A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
12 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Completed NCT00053352 Phase 3 cisplatin;etoposide
13 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
14 Women's Hospital, Zhejiang University School of Medicine Recruiting NCT03885388 Phase 2, Phase 3 MTX;MTX+ACTD
15 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
16 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Bleomycin;Carboplatin;Cisplatin;Etoposide;Etoposide Phosphate
17 A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01535053 Phase 3 Leucovorin Calcium;Methotrexate
18 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
19 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
20 Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma Completed NCT02396511 Phase 2
21 A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor Completed NCT00190918 Phase 2 Pemetrexed
22 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
23 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
24 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
25 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
26 Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients Completed NCT00470366 Phase 2 cisplatin;ifosfamide;paclitaxel
27 Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
28 Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors Completed NCT00301782 Phase 2 carboplatin;cisplatin;etoposide phosphate;vincristine sulfate
29 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
30 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
31 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
32 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
33 A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION Completed NCT00002673 Phase 2
34 Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
35 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
36 Phase II Pre-Irradiation Chemotherapy for Central Nervous System Germ Cell Malignancies Completed NCT00002472 Phase 2 cisplatin;etoposide
37 A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT Completed NCT00047320 Phase 2 carboplatin;etoposide;ifosfamide;thiotepa
38 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Recruiting NCT00432094 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel;thiotepa;Mesna
39 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
40 Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer Active, not recruiting NCT03426865 Phase 2 Axumin PET scan
41 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
42 A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Terminated NCT02664961 Phase 2 TRC105;Bevacizumab
43 Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours Completed NCT00475956 Phase 1 AZD2171;AZD0530
44 A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors Completed NCT00929903 Phase 1 pazopanib hydrochloride
45 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
46 A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination With Fluorouracil and Leucovorin in Pediatric Patients With Advanced Solid Tumors Completed NCT00281944 Phase 1 oxaliplatin;fluorouracil;leucovorin calcium
47 CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00060372 Phase 1 ipilimumab;therapeutic allogeneic lymphocytes
48 A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas Completed NCT00994500 Phase 1 vorinostat;bortezomib
49 A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
50 A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors Completed NCT00387920 Phase 1 sunitinib malate

Search NIH Clinical Center for Choriocarcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: choriocarcinoma

Genetic Tests for Choriocarcinoma

Anatomical Context for Choriocarcinoma

MalaCards organs/tissues related to Choriocarcinoma:

40
Placenta, Lung, Testis, Ovary, Brain, Uterus, Liver

Publications for Choriocarcinoma

Articles related to Choriocarcinoma:

(show top 50) (show all 6350)
# Title Authors PMID Year
1
Nitrofurantoin transport by placental choriocarcinoma JAr cells: involvement of BCRP, OATP2B1 and other MDR transporters. 54 61
19924425 2010
2
Involvement of Heparanase in early pregnancy losses. 54 61
20031192 2010
3
Testicular choriocarcinoma metastatic to skin and multiple organs. Two case reports and review of literature. 54 61
19469863 2010
4
Role of regulatory and angiogenic cytokines in invasion of trophoblastic cells. 54 61
20047586 2010
5
Involvement of transcription factor NR2F2 in human trophoblast differentiation. 54 61
20195529 2010
6
hGH-V gene expression and promoter activity under glucose and 5-azacytidine (5azaC) effects. 54 61
20005926 2010
7
Pulmonary metastases revealing choriocarcinoma. 54 61
20415215 2010
8
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. 54 61
20043267 2010
9
p53 Mediates epidermal growth factor (EGF) induction of MMP-2 transcription and trophoblast invasion. 54 61
19853299 2009
10
CD9 regulates transcription factor GCM1 and ERVWE1 expression through the cAMP/protein kinase A signaling pathway. 54 61
19692500 2009
11
Inhibiton of RET and JAK2 signals and upregulation of VEGFR3 phosphorylation in vitro by galectin-1 in trophoblast tumor cells BeWo. 54 61
19900702 2009
12
Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion. 54 61
19939245 2009
13
Interleukin-11 increases invasiveness of JEG-3 choriocarcinoma cells by modulating STAT3 expression. 54 61
19716605 2009
14
Human chorionic gonadotropin tests. 54 61
19817556 2009
15
Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. 54 61
19805167 2009
16
Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines. 54 61
19758196 2009
17
MyD88 and TRIF mediate the cyclic adenosine monophosphate (cAMP) induced corticotropin releasing hormone (CRH) expression in JEG3 choriocarcinoma cell line. 54 61
19615077 2009
18
Docosahexaenoic acid induces adipose differentiation-related protein through activation of retinoid x receptor in human choriocarcinoma BeWo cells. 54 61
19571381 2009
19
Endometrial carcinoma with choriocarcinomatous differentiation: a case report and review of the literature. 54 61
19232701 2009
20
An aggressive course of de novo ulcerative colitis after renal transplantation: colonic adenocarcinoma with choriocarcinomatous differentiation. 54 61
19927772 2009
21
Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. 54 61
19380797 2009
22
Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells. 54 61
19426551 2009
23
Interleukin-17 increased progesterone secretion by JEG-3 human choriocarcinoma cells. 54 61
19260856 2009
24
Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway. 54 61
19181434 2009
25
Immunohistochemical studies of trophoblastic tumors. 54 61
19145204 2009
26
Metal transcription factor-1 is involved in hypoxia-dependent regulation of placenta growth factor in trophoblast-derived cells. 54 61
19022893 2009
27
Effect of progesterone on HLA-E gene expression in JEG-3 choriocarcinoma cell line. 54 61
19239424 2009
28
Interactions between riluzole and ABCG2/BCRP transporter. 54 61
19146924 2009
29
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. 54 61
19022235 2009
30
Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines. 54 61
19133314 2009
31
Prenatal findings in a case of massive fetomaternal hemorrhage associated with intraplacental choriocarcinoma. 54 61
19293586 2009
32
Human chorionic gonadotropin and associated molecules. 54 61
19099349 2009
33
Up-regulation of placental leptin by human chorionic gonadotropin. 54 61
18787032 2009
34
Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. 54 61
17975728 2008
35
Leptin prevents apoptosis of trophoblastic cells by activation of MAPK pathway. 54 61
18619412 2008
36
Effect of Ad-TIMP3 on biologic behavior of choriocarcinoma cells in vitro. 54 61
18773626 2008
37
Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor. 54 61
18670157 2008
38
A novel mechanism of TGFbeta-induced actin reorganization mediated by Smad proteins and Rho GTPases. 54 61
18631173 2008
39
Immune cell profiling in intraplacental and postmolar choriocarcinomas. 54 61
18773618 2008
40
Expression of glypican 3 in ovarian and extragonadal germ cell tumors. 54 61
18628091 2008
41
Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. 54 61
18066564 2008
42
Endoglin (CD105) expression is regulated by the liver X receptor alpha (NR1H3) in human trophoblast cell line JAR. 54 61
18276933 2008
43
[Effects on human leukocyte antigen-G on proliferation and invasion of JEG-3 cell line]. 54 61
19035141 2008
44
Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation. 54 61
18362896 2008
45
Stimuli through Toll-like receptor (TLR) 3 and 9 affect human chorionic gonadotropin (hCG) production in a choriocarcinoma cell line. 54 61
18412774 2008
46
Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. 54 61
18042733 2008
47
Primary ovarian choriocarcinoma mimicking ectopic pregnancy managed with laparoscopy -- case report. 54 61
18459557 2008
48
Placental site trophoblastic tumor. 54 61
17701427 2008
49
STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. 54 61
19079545 2008
50
Involvement of RelA-associated inhibitor in regulation of trophoblast differentiation via interaction with transcriptional factor specificity protein-1. 54 61
17872376 2007

Variations for Choriocarcinoma

Expression for Choriocarcinoma

Search GEO for disease gene expression data for Choriocarcinoma.

GO Terms for Choriocarcinoma

Cellular components related to Choriocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 HLA-G GH2 CSH2 CSH1 CGB7 CGB5
2 extracellular region GO:0005576 9.32 MGAT4A LNPEP HLA-G GH2 CSH2 CSH1
3 endosome lumen GO:0031904 9.16 GH2 CSH1

Biological processes related to Choriocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.77 LNPEP ENPEP CGB7 CGB5 CGB3
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 GH2 CSH2 CSH1
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 GH2 CSH2 CSH1
4 response to nutrient levels GO:0031667 9.63 GH2 CSH2 CSH1
5 hormone-mediated signaling pathway GO:0009755 9.61 CGB7 CGB5 CGB3
6 positive regulation of JAK-STAT cascade GO:0046427 9.58 GH2 CSH2 CSH1
7 peptide catabolic process GO:0043171 9.54 LNPEP ENPEP
8 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.52 GH2 CSH1
9 female gamete generation GO:0007292 9.5 CGB7 CGB5 CGB3
10 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.48 LNPEP HLA-G
11 peptide hormone processing GO:0016486 9.43 CGB5 CGB3 CGA
12 animal organ development GO:0048513 9.33 GH2 CSH2 CSH1
13 growth hormone receptor signaling pathway GO:0060396 9.13 GH2 CSH2 CSH1
14 positive regulation of growth GO:0045927 8.8 GH2 CSH2 CSH1

Molecular functions related to Choriocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metalloaminopeptidase activity GO:0070006 9.16 LNPEP ENPEP
2 growth hormone receptor binding GO:0005131 9.13 GH2 CSH2 CSH1
3 hormone activity GO:0005179 9.1 GH2 CSH2 CSH1 CGB7 CGB3 CGA

Sources for Choriocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....